Company Overview of Les Laboratoires Servier SAS
Les Laboratoires Servier SAS, a pharmaceutical company, engages in the research and development of reference products to treat various diseases primarily in France. It also produces drugs for clinical trials in cardiovascular disease, endocrinology, oncology, rheumatology, venous disease, ENT, neurosciences, and asthenia product portfolio. Les Laboratoires Servier SAS has a strategic alliance with Galapagos NV; and a strategic collaboration agreement with Cellectis SA. The company was founded in 1954 and is based in Neuilly Sur Seine, France with additional operations in the United States, Australia, Canada, China, and the Russian Federation.
22 Rue Garnier
Neuilly Sur Seine, 92578
Founded in 1954
Key Executives for Les Laboratoires Servier SAS
Manager of Northern Asia Operations
Compensation as of Fiscal Year 2013.
Les Laboratoires Servier SAS Key Developments
Servier and Celladon Corporation Sign Agreement on Diabetes and Metabolic Disorders
Feb 26 14
Servier has announced the signature of an option agreement with Celladon Corporation for a global research collaboration and licence deal targeting novel SERCA2b modulators for the treatment of type 2 diabetes and other metabolic diseases. Celladon will maintain US rights to any compounds and lead candidates developed through this collaboration and licence agreement. Servier's decision to exercise its option will be based on results of a number of pre-defined in vitro and in vivo studies. If Servier decides to exercise its option, Celladon is entitled to obtain an upfront payment as well as milestone payments and royalties on sales. The discovery plan will be jointly supported by the two partners, with Servier responsible for expenses linked to its territory with a global development plan, as well as ex-US regulatory approval and commercialisation of any compound selected as a lead candidate. Financial details were not disclosed by the two companies.
Celladon Corporation Announces Option Agreement with Servier
Feb 24 14
Celladon Corporation announced that Celladon and Servier have entered into an option agreement for a potential worldwide ex-U.S. research collaboration and license agreement for the discovery and development of novel SERCA2b modulators for the treatment of type 2 diabetes and other metabolic diseases. The collaboration would leverage Celladon's novel compounds, proprietary assays, and screening technology for isolation of small molecule modulators of SERCA enzymes. Under the terms of the agreement, Celladon granted Servier an exclusive option to license the worldwide, ex-U.S., rights to the small molecule program in the field of diabetes and other metabolic disorders for a certain period. Servier's decision to exercise its option will be based upon the outcome of a series of pre-defined in vitro and in vivo studies to be performed by the parties. In the event Servier exercises its option, Celladon would receive certain upfront, research support and milestone payments, as well as royalties on sales. Celladon and Servier would jointly support the discovery effort, while Servier would be primarily responsible for all costs associated in and for its territory with a global development plan, as well as ex-U.S. regulatory approval and commercialization of any compound selected as a lead candidate. Celladon would retain all U.S. rights to any compounds and lead candidates developed through this collaboration and license agreement.
Cellectis and Servier Announce Collaboration in Allogeneic Cell Therapy
Feb 18 14
Cellectis announced that it has signed a strategic collaboration agreement with Servier, to develop and commercialize novel product candidates targeting leukemia and solid tumors. The partnership covers the development and potentially the commercialization of Cellectis' lead product candidate, UCART19. Engineered allogeneic CD19 T-cells currently stand out as a real therapeutic innovation for treating various types of leukemias and lymphomas. The agreement also included research, development, and potentially the commercialization of five other product candidates targeting solid tumors. Cellectis will be responsible for the R&D of certain product candidates through the end of Phase I. Servier may exercise an exclusive worldwide option for a license on each product candidate developed under the agreement. Upon exercising each option, Servier will be responsible for taking over clinical development, registration and commercialization of each product. The financial terms of the collaboration include an upfront payment of $10 million and up to $140 million for each of the six product candidates potentially developed, spread over various milestones in the development and commercialization phases. In addition, Cellectis will receive royalties on the sales of commercialized products.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|